What insurance policy changes affect HCPCS J9045?

There are 11 tracked policy changes affecting HCPCS J9045, including updates from Blue Cross Blue Shield of North Dakota, Capital Blue Cross, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J9045?

Payers that have issued tracked updates for HCPCS J9045 include: Blue Cross Blue Shield of North Dakota, Capital Blue Cross, Aetna, Florida Blue, Highmark, Humana.

How do I get notified when HCPCS J9045 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J9045. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J9045?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J9045 — Injection, carboplatin, 50 mg: Insurance Policy Changes

J9045 Insurance Policy Changes

HCPCS J9045 is officially defined as "Injection, carboplatin, 50 mg." HCPCS J9045 is referenced in 11 tracked payer policy changes from Blue Cross Blue Shield of North Dakota, Capital Blue Cross, and 4 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J9045 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact

Bendamustine products (Treanda, Bendeka, Belrapzo, Vivimusta) (Revised)

Humana·Effective Jan 1, 2026

Humana Louisiana Medicaid updated its prior authorization policy for bendamustine products (Treanda, Bendeka, Belrapzo, Vivimusta) effective January 1, 2026, with a revision date of May 1, 2026. The policy establishes specific approval criteria for five indications (CLL, Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, and Waldenström's Macroglobulinemia), with a universal exclusion: members experiencing disease progression on bendamustine-containing regimens are not approved. All bendamustine requests now require prior authorization before dispensing.

J9045 Insurance Policy Changes

Pharmacy Policies Available Online

AB2026-08-002 Medicare only

AB2026-08-001 Updates and new information

Amivantamab-vmjw (Rybrevant) and Amivantamab and Hyaluronidase-lpuj (Rybrevant Faspro) (CPB 0995, reviewed 2026-08-05)

Ramucirumab (Cyramza) (CPB 0883, reviewed 2026-06-03)

Medicare Part B Step Therapy May Updates

Prior Authorization Changes to Oncology-related Codes

Bendamustine products (Treanda, Bendeka, Belrapzo, Vivimusta) (Revised)

Panitumumab (Vectibix) (CPB 0748, reviewed 2025-12-23)

Zolbetuximab-clzb (Vyloy) (CPB 1071, reviewed 2025-12-19)

Penpulimab-kcqx (CPB 1080, reviewed 2026-04-15)